From: Modelling population-level impact to inform target product profiles for childhood malaria vaccines
Category | Settings |
---|---|
Prevalence settings | 5–50% in 5% increments. Four distinct transmission settings, with PfPR2–10 at start year set to 5%, 15%, 30% and 45% |
Simulation size | 30,000–65,000, depending on prevalence level |
Seasonality | Perennial, with Fourier coefficients for the perennial setting as in Walker et al. [22] |
Treatment | 40% coverage of artemisinin-based combination therapy (ACT) treatment with 95% efficacy |
Vaccine coverage | Default value of 80% coverage for the first three vaccine doses, with fourth dose coverage at 80% of the coverage for the first three doses in line with Penny et al. [12]. Varied in the range 50–90% in 5% increments |
Vaccine dose timing | First three RTS,S/AS01 vaccine doses administered at 5, 6.5 and 8 months of age. Fourth dose administered at 26 months (default) and varied in the range 16–30 months |